Health Professionals
Patients & Families
Careers 
BCMA-Targeted CAR T-Cell Therapy for Multiple Myeloma
A personalized cellular immunotherapy investigational approach using a patient’s own immune cells, genetically engineered to express a chimeric antigen receptor (CAR) designed to recognize B-cell maturation antigen (BCMA).
Our research program integrates synthetic immunology, viral vector engineering, and cGMP cell expansion to explore a targeted biological option for patients with difficult-to-treat and relapsed/refractory multiple myeloma.
Understanding Multiple Myeloma
Multiple myeloma is a hematologic malignancy that arises from abnormal plasma cells within the bone marrow. Plasma cells normally generate antibodies that protect the body from pathogen infection.
In multiple myeloma, malignant plasma cells proliferate uncontrollably and accumulate in the marrow, displacing normal hematopoietic elements and causing severe bone lesions, hypercalcemia, renal impairment, anemia, and immune compromise. Despite advances in proteasome inhibitors and immunomodulatory drugs, relapsed disease remains a profound clinical challenge.
Why target BCMA?
B-cell maturation antigen (BCMA, also known as CD269 / TNFRSF17) is a member of the tumor necrosis factor receptor superfamily, critical for plasma cell survival and differentiation.
Importantly, BCMA is selectively and universally expressed across malignant myeloma cells, while being nearly absent on non-hematologic tissues and normal memory B cells. Equipping autologous T cells with a high-affinity synthetic anti-BCMA CAR enables precise redirected immune targeting directly to tumor cells.
How BCMA-targeted CAR T-cell therapy works
Transforming a patient’s own immune cells into an investigational living drug through a multi-step biomanufacturing cycle.
Collecting T cells
Patient’s own white blood cells are collected via a standard leukapheresis procedure, enriched for primary T cells, and transported under temperature-controlled conditions to our cleanrooms.
Engineering T cells
T cells are activated and genetically reprogrammed using a specialized viral vector to integrate the anti-BCMA chimeric antigen receptor construct into the cellular genome.
Expansion & QC
Engineered CAR T cells proliferate in automated closed bioreactors, undergoing multi-point analytical testing for viability, vector copy number, sterility, and target cytolytic activity.
Returning cells
Following lymphodepleting preparation, the personalized cellular product is cryopreserved, shipped via verified vapor shipper, and infused intravenously to seek out BCMA-positive targets.
The 6-Step Development Roadmap
Because this program is in research and development, this pathway reflects the generalized prospective protocol design for autologous BCMA cellular therapy.
Medical Evaluation
Multidisciplinary assessment of cytogenetics, previous lines of therapy, bone marrow plasma cell infiltration, ECOG score, and organ fitness.
T-Cell Collection
Outpatient or inpatient apheresis yields sufficient mononuclear cells with cryopreservation reserves for manufacturing backup.
CAR Engineering
T-cell genetic transduction, culture expansion, and exhaustive release testing across a standardized 14-to-21 day bioprocessing timeline.
Conditioning Chemotherapy
Short course of lymphodepleting chemotherapy (fludarabine/cyclophosphamide) to create a hospitable microenvironment for CAR T expansion.
Targeted Infusion
Single intravenous infusion of the autologous drug product conducted in specialized bone marrow transplant or cellular therapy hospital suites.
Post-Infusion Monitoring
Inpatient safety surveillance for CRS and neurotoxicity, followed by serial bone marrow and serum paraprotein response assessments.
Mechanism of Action & Biological Foundation
The BCMA CAR-T program brings together immunology, synthetic receptors, and cell biomanufacturing to direct precision immune elimination.
Biological Sequence
Synthetic Immunology
Tailored scFv binding domains providing high affinity with calibrated persistence.
Vector Engineering
Safe integration profiles minimizing genotoxicity and maximizing functional expression.
Cellular Bioprocessing
Closed bioreactor cultivation ensuring young memory-like T-cell phenotypes.